Caladrius Biosciences Inc., a clinical-stage biopharmaceutical company based in Basking Ridge, has been on the hunt for “strategic development opportunities” this past year, according to President and ...

Not an acquisition but a “merger of equals.” That’s how Caladrius Biosciences and Cend Therapeutics have described their transformation into the newly christened Lisata Therapeutics. The all-stock ...

On Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110%. However, the surge did not come off the back of a treatment’s regulatory ...

Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong ...

As Caladrius Biosciences merges with Cend Therapeutics to become Lisata Therapeutics, it’s leaving a coronary artery disease trial by the wayside. The biotech announced plans to shelve, at least for ...

Caladrius reported in May 2020 the compelling positive results of its ESCaPE-CMD Phase 2a study of CLBS16 for the treatment of coronary microvascular dysfunction (“CMD”), a disease that continues to ...

BASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...